<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184743</url>
  </required_header>
  <id_info>
    <org_study_id>GHLIQUID-1519</org_study_id>
    <secondary_id>JapicCTI-050133</secondary_id>
    <nct_id>NCT00184743</nct_id>
  </id_info>
  <brief_title>Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)</brief_title>
  <official_title>Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. To investigate the long-term efficacy as assessed by change
      in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with Growth
      Hormone Deficiency, comparing two different treatment regiments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2003</start_date>
  <completion_date type="Actual">December 28, 2005</completion_date>
  <primary_completion_date type="Actual">December 28, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in truncal fat (kg)</measure>
    <time_frame>from the baseline to the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total body fat, Total LBM, etc. from the baseline to the end of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid-related laboratory tests (total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG, insulin, and HbA1C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-I SDS, IGFBP-3 SDS, and IGF-I/IGFBP-3 molar ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
  </secondary_outcome>
  <enrollment type="Actual">112</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who completed GHLiquid-1518.

          -  If the subject has a history of treatment for a tumor of pituitary or peripheral site,
             two years or more have to be passed since completion of surgery, radiotherapy or other
             treatment, and recurrence of the underlying disease to be excluded.

          -  Appropriate replacement therapy has been administered for more than 24 weeks for the
             treatment of other pituitary hormone deficiencies.

        Exclusion Criteria:

          -  Subject with a history of acromegaly.

          -  Subject with diabetes mellitus.

          -  Subject suffering from malignancy.

          -  Several medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

